摘要
目的:探讨参芪扶正注射液联合索拉非尼对肝癌术后患者微小RNA(miR)-103、趋化因子受体(CXCR)3、甲胎蛋白(AFP)的影响。方法:选取肝癌术后患者88例,根据随机数字表法分研究组与对照组患者各44例。对照组患者给予索拉非尼治疗,研究组患者在对照组治疗的基础上给予参芪扶正注射液治疗观察,12周,记录miR-103、CXCR3、AFP变化情况。结果:治疗后研究组患者总有效率为97.7%,显著高于对照组患者的86.4%(P<0.05)。治疗期间两组患者不良反应差异均无统计学意义(均P>0.05)。两组血清CXCR3、AFP含量治疗后显著低于治疗前(P<0.05),且研究组患者显著低于对照组(P<0.05)。两组治疗后的血miR-103相对表达水平都低于治疗前(P<0.05),研究组患者显著低于对照组(P<0.05)。两组治疗后的CD4^+值显著高于治疗前,CD8^+值低于治疗前,差异有统计学意义(P<0.05);两组比较差异有统计学意义(P<0.05)。结论:参芪扶正注射液联合索拉非尼能抑制肝癌术后患者miR-103、CXCR3、AFP的表达,提高机体的免疫功能,且不会增加不良反应的发生。
Objective:To investigate the effects of microRNA(miR)-103,Chemokine receptor(CXCR)3,and alpha-fetoprotein(AFP)of Shenqi Fuzheng Injection combined with sorafenib on postoperative patients with liver cancer.Methods:From September 2015 to December 2018,88 patients with liver cancer who were treated in our hospital were selected and were equally divided into the study group and control group accorded to the random number table method.The control group were treated with sorafenib,the study group were treated with Shenqi Fuzheng Injection on the basis of the control group.The treatment were observed for 12 weeks,and the changes of miR-103,CXCR3 and AFP were recorded.Result:The total effective rate of the study group after treatment were 97.7%,which were significantly higher than that of the control group(86.4%)(P<0.05).The adverse reactions during the two groups were mainly blood system reaction,digestive tract reaction,skin reaction,liver and kidney function response,and compared the difference were not statistically significant(P>0.05).The serum levels of CXCR3 and AFP in the two groups were significantly lower than those before treatment(P<0.05),and the study group were also significantly lower than the control group(P<0.05).The relative expression levels of miR-103 in the two groups were lower than those before treatment(P<0.05),and the study group were also significantly lower than the control group(P<0.05).The CD4^+ values of the two groups were significantly higher than those before treatment,and the CD+8 values were lower than those before treatment.The difference were statistically significant(P<0.05),and the difference compared between the study group and the control group were statistically significant(P<0.05).Conclusion:Shenqi Fuzheng injection combined with sorafenib in patients with liver cancer can inhibit the expression of miR-103,CXCR3 and AFP,improve the immune function of the body,and will not increase the incidence of adverse reactions,thus improving treatment efficacy.
作者
陆晓怡
华国栋
白洁
田晓玲
刘诚
李永恒
LU Xiaoyi;HUA Guodong;BAI Jie(The Pharmacy,Dong Fang Hospital of Beijing University of Chinese Medicine,Beijing,100078 China)
出处
《中西医结合肝病杂志》
CAS
2020年第3期218-220,230,I0004,共5页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金
北京市属医院科研培育计划项目(No.PX20160008)。
作者简介
通讯作者:华国栋,E-mail:zhaojhuagd@126.com。
